Skye BioScience (Skye Bioscience inc (OTCQB:SKYE)) Presenting at the Proactive One2One Virtual Forum - 4th November 2021
We are a biopharmaceutical company engineering proprietary cannabinoid derivatives to treat glaucoma and other diseases with significant unmet medical needs Our innovative approach to drug development enables us to transform cannabinoids into safer, more effective pharmaceutical agents. By advancing our novel drugs, we are working to bring important new medicines to market by unlocking the potential of cannabinoids.